Related Experiment Videos
Albendazole for lymphatic filariasis
The Cochrane Database of Systematic Reviews
|February 20, 2004
Summary
Limited research suggests albendazole, alone or with other drugs, may not effectively treat lymphatic filariasis. More studies are needed to confirm its impact on microfilaraemia and overall efficacy in eliminating this parasitic disease.
Area of Science:
- Tropical Medicine
- Infectious Diseases
- Parasitology
Background:
- Mass treatment with albendazole is a key strategy for global lymphatic filariasis elimination.
- Albendazole is often co-administered with diethylcarbamazine or ivermectin.
Purpose of the Study:
- To evaluate albendazole's effects on filarial infection and morbidity.
- To assess adverse events of albendazole, alone or combined with other antifilarial drugs.
Main Methods:
- Systematic review of randomized and quasi-randomized controlled trials.
- Searched multiple databases including Cochrane, MEDLINE, EMBASE, and LILACS.
- Meta-analysis used fixed or random effects models to calculate relative risks.
Main Results:
- Four small studies (2473 participants) met inclusion criteria.
- Albendazole showed no effect on microfilaraemia compared to placebo.
- Albendazole was less effective than ivermectin; efficacy was similar to diethylcarbamazine.
- Combination therapy results were mixed, with no consistent improvement in microfilaraemia.
Conclusions:
- Insufficient evidence exists to confirm albendazole's efficacy for lymphatic filariasis.
- Further research is required to determine the role of albendazole in mass drug administration programs.